ATE367396T1 - Rapamycin-carbohydrate derivate - Google Patents

Rapamycin-carbohydrate derivate

Info

Publication number: ATE367396T1
Authority: AT; Austria
Prior art keywords: rapamycin; rapamycin carbohydrate; derivatives; carbohydrate derivatives; profiles
Prior art date: 2003-05-16

Application number

AT04732898T

Other languages

English (en)

Inventor

Mark Abel

Roman Szweda

Daniel Trepanier

Randall Yatscoff

Robert Foster

Original Assignee

Isotechnika Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-16

Filing date

2004-05-14

Publication date

2007-08-15

2004-05-14 Application filed by Isotechnika Inc filed Critical Isotechnika Inc

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE367396T1 publication Critical patent/ATE367396T1/de

Links

ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
229960002930 sirolimus Drugs 0.000 title abstract 4
-1 RAPAMYCIN CARBOHYDRATE DERIVATIVES Chemical class 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002772 monosaccharides Chemical class 0.000 abstract 1
229920001542 oligosaccharide Polymers 0.000 abstract 1
150000002482 oligosaccharides Chemical class 0.000 abstract 1
230000003285 pharmacodynamic effect Effects 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Crystallography & Structural Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Prostheses (AREA)

AT04732898T 2003-05-16 2004-05-14 Rapamycin-carbohydrate derivate ATE367396T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US47136703P	2003-05-16	2003-05-16
US54624004P	2004-02-20	2004-02-20
US56284004P	2004-04-16	2004-04-16

Publications (1)

Publication Number	Publication Date
ATE367396T1 true ATE367396T1 (de)	2007-08-15

Family

ID=33458770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04732898T ATE367396T1 (de)	2003-05-16	2004-05-14	Rapamycin-carbohydrate derivate

Country Status (19)

Country	Link
US (3)	US7160867B2 (de)
EP (2)	EP1644392B1 (de)
JP (1)	JP2007503452A (de)
KR (1)	KR20060031603A (de)
AT (1)	ATE367396T1 (de)
AU (1)	AU2004238408A1 (de)
BR (1)	BRPI0411171A (de)
CA (1)	CA2525907A1 (de)
DE (1)	DE602004007662T2 (de)
DK (1)	DK1644392T3 (de)
ES (1)	ES2286637T3 (de)
HR (1)	HRP20070383T3 (de)
MX (1)	MXPA05012376A (de)
NO (1)	NO20055283L (de)
NZ (1)	NZ543479A (de)
PL (1)	PL1644392T3 (de)
PT (1)	PT1644392E (de)
TW (1)	TW200511991A (de)
WO (1)	WO2004101583A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6955661B1 (en)	1999-01-25	2005-10-18	Atrium Medical Corporation	Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
US8021331B2 (en) *	2003-09-15	2011-09-20	Atrium Medical Corporation	Method of coating a folded medical device
JP2007505932A (ja) *	2003-09-18	2007-03-15	マクサイト，インコーポレイテッド	経強膜送達
US7563780B1 (en) *	2004-06-18	2009-07-21	Advanced Cardiovascular Systems, Inc.	Heparin prodrugs and drug delivery stents formed therefrom
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
CA2597590A1 (en)	2005-02-09	2006-08-17	Macusight, Inc.	Formulations for ocular treatment
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
EP1888137A2 (de) *	2005-04-29	2008-02-20	Atrium Medical Corporation	Arzneistoffzuführungsbeschichtung zur verwendung mit einer medizinischen vorrichtung sowie verfahren zur behandlung von gefässverletzung
PT2275103E (pt)	2005-11-21	2014-07-24	Novartis Ag	Inibidores de mtor para o tratamento de tumores endócrinos
KR101478164B1 (ko)	2006-02-09	2014-12-31	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en)	2006-03-23	2012-07-19	Santen Pharmaceutical Co., Ltd.	Formulations and methods for vascular permeability-related diseases or conditions
GB0609963D0 (en) *	2006-05-19	2006-06-28	Biotica Tech Ltd	Novel compounds
US20080265343A1 (en) *	2007-04-26	2008-10-30	International Business Machines Corporation	Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090253733A1 (en) *	2008-04-02	2009-10-08	Biointeractions, Ltd.	Rapamycin carbonate esters
CN101676291B (zh) *	2008-09-18	2012-05-09	上海海和药物研究开发有限公司	一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
CA2937492C (en)	2008-11-11	2019-08-13	The Board Of Regents Of The University Of Texas System	Inhibition of mammalian target of rapamycin
WO2010080863A1 (en)	2009-01-07	2010-07-15	Wisconsin Alumni Research Foundation	Enhanced neoglycosides through neoglycosylation and methods of use thereof
WO2011024168A2 (en)	2009-08-26	2011-03-03	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd	Sustained release delivery systems for the prevention and treatment of head and neck cancers
US10391059B2 (en)	2009-11-11	2019-08-27	Rapamycin Holdings, Inc.	Oral rapamycin nanoparticle preparations and use
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
RU2603261C2 (ru) *	2011-04-01	2016-11-27	Сандоз Аг	Региоселективное ацилирование рапамицина в положении с-42
EP2589383A1 (de)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
JP2015512371A (ja)	2012-03-23	2015-04-27	ザ・ユニバーシティ・オブ・クイーンズランド	免疫調節性作用物質およびその使用
CN104203959B (zh) *	2012-06-08	2017-09-15	百多力股份公司	雷帕霉素40‑o‑环状烃酯、组合物和方法
US10751450B2 (en)	2012-06-08	2020-08-25	Biotronik Ag	Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
US20160030401A1 (en)	2013-03-13	2016-02-04	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
WO2014184734A1 (en)	2013-05-14	2014-11-20	Novartis Ag	Markers associated with mtor inhibition
AU2014293013A1 (en)	2013-07-26	2016-03-17	Race Oncology Ltd.	Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015044854A1 (en)	2013-09-24	2015-04-02	Novartis Ag	Markers associated with mtor inhibition
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
US10442835B2 (en)	2016-05-10	2019-10-15	Zhejiang Hisun Pharmaceutical Co., Ltd.	Water-soluble rapamycin derivatives
EP3848065B1 (de)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
PL3788049T3 (pl)	2018-05-01	2023-06-19	Revolution Medicines, Inc.	Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (de)	2018-05-01	2024-08-28	Revolution Medicines, Inc.	C26-verknüpfte rapamycinanaloga als mtor-inhibitoren
JP7262581B2 (ja)	2018-11-14	2023-04-21	ルトニックス，インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CA3127448C (en)	2019-01-22	2024-06-04	Aeovian Pharmaceuticals, Inc.	Mtorc modulators and uses thereof
CN113939324A (zh)	2019-04-08	2022-01-14	巴德外周血管股份有限公司	在经改性装置表面上具有药物洗脱涂层的医疗装置
EP4531859A4 (de)	2022-05-25	2026-05-27	Revolution Medicines Inc	Verfahren zur behandlung von krebs mit einem mtor-inhibitor

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3226179A (en) *	1962-10-01	1965-12-28	Huyck Corp	Papermaker's felt, woven fabrics and fibers of wool modified with an aldehyde - 4,4 - bis(4 - hydroxy phenyl) pentanoic acid reaction product and the production thereof
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4316685A (en) *	1980-02-29	1982-02-23	Black & Decker Inc.	Plunge type router
US4316885A (en)	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4650803A (en)	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023263A (en)	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
US5378696A (en)	1990-09-19	1995-01-03	American Home Products Corporation	Rapamycin esters
US5358944A (en)	1990-09-19	1994-10-25	American Home Products Corporation	Rapamycin esters for treating transplantation rejection
PT98990A (pt)	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
JPH06502659A (ja)	1991-05-31	1994-03-24	ファイザー　インク	免疫抑制剤としてのラパマイシンプロドラッグの使用
US5457111A (en)	1991-09-05	1995-10-10	Abbott Laboratories	Macrocyclic immunomodulators
US5162333A (en)	1991-09-11	1992-11-10	American Home Products Corporation	Aminodiesters of rapamycin
JP2564765B2 (ja)	1992-03-02	1996-12-18	ファイザー・インコーポレーテッド	マクロライド系抗生物質のフルオロ糖誘導体
FI944014A0 (fi)	1992-03-02	1994-09-01	Pfizer	Makrolidien desosaminojohdannaiset immuunivastetta heikentävinä aineina ja sieniä vastustavina aineina
CA2131373C (en)	1992-03-02	1999-01-26	Kevin Koch	2-aminosugar derivatives of macrolides
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5434260A (en)	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
DE4236237A1 (de)	1992-10-27	1994-04-28	Behringwerke Ag	Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5262423A (en)	1992-10-29	1993-11-16	American Home Products Corporation	Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en)	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
USRE37421E1 (en)	1993-07-16	2001-10-23	Smithkline Beecham Corporation	Rapamycin derivatives
EP0729471A1 (de)	1993-11-19	1996-09-04	Abbott Laboratories	Semisynthetische rapamycin analoge mit immunomodulatorischer wirkung
US5527907A (en)	1993-11-19	1996-06-18	Abbott Laboratories	Macrolide immunomodulators
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5563145A (en)	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
JPH11504028A (ja)	1995-04-24	1999-04-06	イースムリサーチディベロップメントカンパニーオブザヒーブルユニバーシティオブエルサレム	油／水エマルジョンを作り出す自己乳化性配合物
US6187757B1 (en)	1995-06-07	2001-02-13	Ariad Pharmaceuticals, Inc.	Regulation of biological events using novel compounds
DE69624921T2 (de)	1995-06-09	2003-09-11	Novartis Ag, Basel	Rapamycinderivate
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DK0795334T3 (da)	1996-03-12	2006-06-06	Sanofi Aventis Deutschland	Nye prodrugs til behandling af tumorer og betændelsessygdomme
US6103884A (en)	1996-03-27	2000-08-15	The University Of Michigan	Glycosylated analogs of fusidic acid
DE69736750T2 (de)	1996-07-30	2007-08-16	Novartis Ag	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6884429B2 (en) *	1997-09-05	2005-04-26	Isotechnika International Inc.	Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6342507B1 (en)	1997-09-05	2002-01-29	Isotechnika, Inc.	Deuterated rapamycin compounds, method and uses thereof
US6153252A (en)	1998-06-30	2000-11-28	Ethicon, Inc.	Process for coating stents
US6015809A (en)	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
JP4647792B2 (ja) *	1999-04-28	2011-03-09	イジュノシッヒテクニッヒホッフシューラチューリッヒ	分析用デバイスおよびセンシングデバイスにおけるポリイオン性コーティング
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US6670355B2 (en) *	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives

2004
- 2004-05-13 US US10/845,747 patent/US7160867B2/en not_active Expired - Fee Related
- 2004-05-14 AT AT04732898T patent/ATE367396T1/de not_active IP Right Cessation
- 2004-05-14 KR KR1020057021769A patent/KR20060031603A/ko not_active Ceased
- 2004-05-14 WO PCT/CA2004/000724 patent/WO2004101583A1/en not_active Ceased
- 2004-05-14 BR BRPI0411171-0A patent/BRPI0411171A/pt not_active IP Right Cessation
- 2004-05-14 JP JP2006529489A patent/JP2007503452A/ja not_active Withdrawn
- 2004-05-14 MX MXPA05012376A patent/MXPA05012376A/es active IP Right Grant
- 2004-05-14 TW TW093113648A patent/TW200511991A/zh unknown
- 2004-05-14 EP EP04732898A patent/EP1644392B1/de not_active Expired - Lifetime
- 2004-05-14 PL PL04732898T patent/PL1644392T3/pl unknown
- 2004-05-14 AU AU2004238408A patent/AU2004238408A1/en not_active Abandoned
- 2004-05-14 HR HR20070383T patent/HRP20070383T3/xx unknown
- 2004-05-14 NZ NZ543479A patent/NZ543479A/en unknown
- 2004-05-14 ES ES04732898T patent/ES2286637T3/es not_active Expired - Lifetime
- 2004-05-14 PT PT04732898T patent/PT1644392E/pt unknown
- 2004-05-14 EP EP07003243A patent/EP1785430A1/de not_active Withdrawn
- 2004-05-14 DK DK04732898T patent/DK1644392T3/da active
- 2004-05-14 CA CA002525907A patent/CA2525907A1/en not_active Abandoned
- 2004-05-14 DE DE602004007662T patent/DE602004007662T2/de not_active Expired - Fee Related
2005
- 2005-09-15 US US11/229,007 patent/US20060079466A1/en not_active Abandoned
- 2005-11-10 NO NO20055283A patent/NO20055283L/no not_active Application Discontinuation
2006
- 2006-11-09 US US11/595,397 patent/US20070099848A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7160867B2 (en)	2007-01-09
JP2007503452A (ja)	2007-02-22
ES2286637T3 (es)	2007-12-01
DK1644392T3 (da)	2007-11-12
MXPA05012376A (es)	2006-05-25
KR20060031603A (ko)	2006-04-12
HRP20070383T3 (hr)	2007-10-31
US20060079466A1 (en)	2006-04-13
EP1785430A1 (de)	2007-05-16
US20040235762A1 (en)	2004-11-25
DE602004007662T2 (de)	2007-11-22
PT1644392E (pt)	2007-08-03
TW200511991A (en)	2005-04-01
EP1644392A1 (de)	2006-04-12
BRPI0411171A (pt)	2006-07-18
AU2004238408A1 (en)	2004-11-25
US20070099848A1 (en)	2007-05-03
WO2004101583A1 (en)	2004-11-25
NZ543479A (en)	2008-03-28
PL1644392T3 (pl)	2007-12-31
CA2525907A1 (en)	2004-11-25
NO20055283D0 (no)	2005-11-10
NO20055283L (no)	2005-12-16
EP1644392B1 (de)	2007-07-18
DE602004007662D1 (de)	2007-08-30

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1644392

Country of ref document: EP

2011-02-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE602004007662D1 (de)	2007-08-30	Rapamycin-carbohydrate derivate
PL374523A1 (pl)	2005-10-31	Koniugaty pochodna kalicheamycyny-nośnik
IL189187A (en)	2013-04-30	Polymeric couplings of a252-k and their history, their pharmaceutical preparations and their uses
DK1592699T3 (da)	2007-05-07	Avermectin og avermectin-monosaccharidderivater substitueret i 4"- eller 4' -positionen, hvilke forbindelser har pesticidegenskaber
FR2882054B1 (fr)	2007-04-13	Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
DK1594878T3 (da)	2008-10-06	Avermectin-monosaccharidderivater med pesticidegenskaber
DE602005015835D1 (de)	2009-09-17	An der 4"- bzw. 4'-stellung substituiertes avermectin und avermectin-monosaccharid
WO2007075972A3 (en)	2008-12-04	Chlorite formulations, and methods of preparation and use thereof
ATE237359T1 (de)	2003-05-15	Zyklodextrin-zusammensetzung enthaltend ein avermectin- oder ein milbemycin-derivat
MA29016B1 (fr)	2007-11-01	Derives de pyridine, leur preparation, leur application en therapeutique
FR2891825B1 (fr)	2007-12-14	Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique
DK1592700T3 (da)	2008-08-04	Avermectin-derivater og Avermectin-monosaccharidderivater der er substitueret i 4'' - eller 4' - stillingen, og som har pesticidegenskaber
DK1079840T3 (da)	2002-11-04	Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer
WO2004026319A3 (en)	2004-09-02	Pharmaceutical compositions increasing camp useful for the treatment of cancers
FR2896246B1 (fr)	2008-08-15	Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
FR2887548B1 (fr)	2007-09-21	Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
CY1110787T1 (el)	2015-06-10	Νεα μορφινικα παραγωγα
WO2009032286A3 (en)	2012-01-12	Oligomer-calcium channel blocker conjugates
AP2007004174A0 (en)	2007-10-31	Substituted aryl 1,4-pyrazine derivatives
ATE370157T1 (de)	2007-09-15	Avermectin-b1-monosaccharidderivative
FR2887249B1 (fr)	2007-09-28	Compose d-glucopyranose 1-[3,5-bis(1,1-dimenthylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations
BRPI0410638A (pt)	2006-06-13	derivados de azitromicina
FR2893615B1 (fr)	2008-03-07	Derives de 3-acylindole, leur preparation et leur application en therapeutique
WO2005116041A3 (en)	2006-08-24	New aminoglycoside compounds and derivatives thereof
FR2889847B1 (fr)	2007-10-05	Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.